Bayer and Veracyte have entered a collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer.
Servier has entered into an agreement for the acquisition of Agios Pharmaceuticals' oncology business including its commercial, clinical and research-stage oncology portfolio for up to $2 billion, including an upfront payment of $1.8 Billion and a potential $200 million in regulatory milestone, plus royalties.
Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.
A study funded by Cancer Research UK shows that the immune response to COVID-19 is the same in people with solid tumors compared to those without cancer.
Researchers from the University of Cincinnati have identified a framework that could help people with serious health conditions keep up their lung cancer screening appointments during the current surge.
Scientists at the USC Center for Genetic Epidemiology and the Institute for Cancer Research, London, led a study that brings together data from the majority of genomic prostate cancer studies globally.
The National Comprehensive Cancer Network published two new Guidelines for Patients on healthy living and managing late and long-term side effects, and include appropriate ongoing screening for recurrence.
Researchers from SWOG Cancer Research Network have demonstrated that a triple drug combination—of irinotecan, cetuximab, and vemurafenib—is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
Miami Cancer Institute, part of Baptist Health South Florida, has initiated several clinical trials based on treatments from initial emergency and experimental COVID-19 therapies.
A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) demonstrated statistically significant improvement in overall survival, progression-free survival and objective response rate versus chemotherapy in patients with advanced endometrial cancer.
